UGCG and viral infectious disease: Indeed, NB-DNJ has been approved for clinical use since 2002 as a second-line treatment for Gaucher disease (GD).20 In this context, NB-DNJ is used as an inhibitor of UGCG to reduce the production of glycosphingolipids that accumulate due to a deficiency in GlcCer degradation.21 The antiviral activity of specific UGCG inhibitors in viral infection of the CNS has not been examined in vivo or in vitro.